Table 2.

Adverse events in Phase II randomised controlled clinical trial for vorinostat (VOR)/hydroxychloroquine (HCQ) versus regorafenib (RGF) in refractory metastatic colorectal cancer (mCRC).

RGF: adverse events by grade
Grade	1	2	3	4
n (%)	54	31	11	2
AE
Anaemia	2 (3.7)	0 (0.0)	0 (0.0)	0 (0.0)
Anorexia	1 (1.9)	0 (0.0)	0 (0.0)	0 (0.0)
Bloating	1 (1.9)	0 (0.0)	0 (0.0)	0 (0.0)
Blood bilirubin increase	0 (0.0)	5 (16.1)	1 (9.1)	0 (0.0)
Chills	1 (1.9)	0 (0.0)	0 (0.0)	0 (0.0)
Conjunctivitis	1 (1.9)	1 (3.2)	0 (0.0)	0 (0.0)
Constipation	2 (3.7)	0 (0.0)	0 (0.0)	0 (0.0)
Diarrhoea	3 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)
Dysgeusia	1 (1.9)	0 (0.0)	0 (0.0)	0 (0.0)
Fatigue	5 (9.3)	3 (9.7)	1 (9.1)	0 (0.0)
Glucose intolerance	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)
Hypertension	1 (1.9)	0 (0.0)	1 (9.1)	0 (0.0)
Hypoalbuminemia	1 (1.9)	0 (0.0)	0 (0.0)	0 (0.0)
Hypokalemia	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)
Laryngeal inflammation	1 (1.9)	0 (0.0)	0 (0.0)	0 (0.0)
Lung infection	0 (0.0)	1 (3.2)	0 (0.0)	0 (0.0)
Mucositis	8 (14.8)	3 (9.7)	0 (0.0)	0 (0.0)
Nail discoloration	1 (1.9)	0 (0.0)	0 (0.0)	0 (0.0)
Nausea	1 (1.9)	1 (3.2)	0 (0.0)	0 (0.0)
Neutrophil count decreased	0 (0.0)	1 (3.2)	0 (0.0)	0 (0.0)
Palmar-plantar erythrodysesthesia syndrome	9 (16.7)	12 (38.7)	1 (9.1)	0 (0.0)
Platelet count decreased	4 (7.4)	1 (3.2)	1 (9.1)	1 (50.0)
Pruritus	2 (3.7)	0 (0.0)	0 (0.0)	0 (0.0)
Rash maculopapular	1 (1.9)	1 (3.2)	0 (0.0)	0 (0.0)
Transferase increase	3 (5.6)	2 (6.5)	4 (36.4)	1 (50.0)
Voice alteration	2 (3.7)	0 (0.0)	0 (0.0)	0 (0.0)
Vomiting	1 (1.9)	0 (0.0)	0 (0.0)	0 (0.0)
White blood cell decreased	2 (3.7)	0 (0.0)	0 (0.0)	0 (0.0)

n number.

Grade of adverse events by NCI CTCAE v3.0.